Literature DB >> 6302214

Coronavirus IBV glycopolypeptides: size of their polypeptide moieties and nature of their oligosaccharides.

D Cavanagh.   

Abstract

Analysis of differentially radiolabelled avian infectious bronchitis virus (IBV) indicated that the matrix (M) polypeptides of mol. wt. 23 X 10(3) (23K), 26K, 28K, 30K and 34K (M23 to M34) which have been shown to give the same peptide maps, differed in their degree of glycosylation; M23 was not glycosylated while glycosylation increased with increasing mol. wt. from M26 to M34. Both glucosamine and mannose were components of M26 to M34 but [3H]fucose appeared to be associated mainly with M34. Endo-beta-N-acetylglucosaminidase H removed oligosaccharides from M28 and M30 but not M26 and M34, to give a polypeptide of 23K. The surface projection glycopolypeptides S1 (90K) and S2 (84K) incorporated 3H-labelled glucosamine and mannose but not fucose and had oligosaccharides removed by endoglycosidase H. The mol. wt. of the resultant polypeptides varied among experiments; the lowest mol. wt. observed were 64K and 61K. These results indicate (i) that the polypeptide moieties of the S polypeptides are approximately 64K and 61K, and 23K for the M polypeptide, (ii) that the oligosaccharides of the S and M polypeptides are of the high-mannose type and are linked to the polypeptides by N-glycosidic linkages, and (iii) that the M glycoprotein of IBV differs from that of murine coronaviruses and bovine coronavirus L9 which have O-linked oligosaccharides.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302214     DOI: 10.1099/0022-1317-64-5-1187

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  26 in total

1.  Analysis of the serotype-specific epitopes of avian infectious bronchitis virus strains Ark99 and Mass41.

Authors:  W Jia; X Wang; C R Parrish; S A Naqi
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

2.  Antigenic and genomic relationships among turkey and bovine enteric coronaviruses.

Authors:  S Dea; A J Verbeek; P Tijssen
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

3.  Organization of two transmissible gastroenteritis coronavirus membrane protein topologies within the virion and core.

Authors:  D Escors; E Camafeita; J Ortego; H Laude; L Enjuanes
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Localization of a T-cell epitope within the nucleocapsid protein of avian coronavirus.

Authors:  A M Boots; J G Kusters; J M van Noort; K A Zwaagstra; E Rijke; B A van der Zeijst; E J Hensen
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

5.  MHC class II-restricted T-cell hybridomas recognizing the nucleocapsid protein of avian coronavirus IBV.

Authors:  A M Boots; M J Van Lierop; J G Kusters; P J Van Kooten; B A Van der Zeijst; E J Hensen
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

6.  Protein synthesis in cells infected by murine hepatitis viruses JHM and A59: tryptic peptide analysis.

Authors:  C W Bond; K Anderson; J L Leibowitz
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

7.  Utilization of DC-SIGN for entry of feline coronaviruses into host cells.

Authors:  Andrew D Regan; Gary R Whittaker
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

8.  The S1 glycoprotein but not the N or M proteins of avian infectious bronchitis virus induces protection in vaccinated chickens.

Authors:  J Ignjatovic; L Galli
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Emergence of variant avian infectious bronchitis virus in India.

Authors:  A Raja; G Dhinakar Raj; K Kumanan
Journal:  Iran J Vet Res       Date:  2020       Impact factor: 1.376

10.  Novel coronavirus-like particles targeting cells lining the respiratory tract.

Authors:  Antonina Naskalska; Agnieszka Dabrowska; Paulina Nowak; Artur Szczepanski; Krzysztof Jasik; Aleksandra Milewska; Marek Ochman; Slawomir Zeglen; Zenon Rajfur; Krzysztof Pyrc
Journal:  PLoS One       Date:  2018-09-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.